Management issues in chronic viral hepatitis: hepatitis C.

Area of Science:

• Hepatology and Virology
• Infectious Diseases
• Pharmacotherapy

Background:

• Chronic hepatitis C virus (HCV) infection presents challenges in predicting disease progression and optimizing antiviral treatment.
• Identifying patients likely to develop severe liver disease early is crucial for timely and effective intervention.
• Significant therapeutic advancements have been made in managing chronic HCV over the last decade.

Purpose of the Study:

• To review the natural history of chronic HCV infection and the role of antiviral interventions.
• To highlight the significance of sustained virological response (SVR) as a key indicator of treatment success.
• To discuss current and emerging treatment strategies, including interferon-based therapies.

Main Methods:

• Review of current literature on chronic hepatitis C virus (HCV) infection natural history and antiviral therapy.
• Analysis of treatment response factors, including host (age, gender), disease (fibrosis), and viral (genotype, load) characteristics.
• Evaluation of different therapeutic regimens, such as interferon monotherapy, interferon with ribavirin, and pegylated interferon combinations.

Main Results:

• Sustained virological response (SVR) is the primary endpoint, indicating a cure and improved quality of life.
• Treatment efficacy varies by HCV genotype; genotype 1 shows lower SVR rates (approx. 30%) compared to genotypes 2/3 (approx. 65%).
• Combination therapy with pegylated interferon and ribavirin is emerging as the new standard, with monotherapy an option for ribavirin-intolerant patients.

Conclusions:

• Achieving SVR signifies a cure for HCV infection, leading to sustained improvements in liver health and patient well-being.
• Treatment strategies must consider individual patient factors and viral characteristics for optimal outcomes.
• Clinicians must be aware of potential side effects and provide comprehensive patient counseling and monitoring.